Alluvi, known as BI 4744, represents a notable development in weight control care. This dual stimulator targeting both glucagon-like peptide-1 and GIP sites demonstrates impressive effectiveness in clinical studies, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/